Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 401–500 of 1,001
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold
Schmäche, T., Fohgrub, J., Klimová, A., Laaber, K., Drukewitz, S., Merboth, F., Hennig, A., Seidlitz, T., Herbst, F., Baenke, F., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01919-3 · Cited by 62
“A correlation between PDO and patient response could already be established for EGCs in selected cases [9].”
BackgroundKim, H. N., Habbit, N. L., Su, C., Choi, N., Ahn, E. H., Lipke, E. A., & Kim, D. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807553 · Cited by 57
Derouet, M. F., Allen, J., Wilson, G. W., Ng, C., Radulovich, N., Kalimuthu, S., Tsao, M.-S., Darling, G. E., & Yeung, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-71589-4 · Cited by 54
Bioink: a 3D-bioprinting tool for anticancer drug discovery and cancer management
Pandey-Tiwari, A., Thorat, N. D., Pricl, S., Patil, R. M., Rohiwal, S. S., & Townley, H. E. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.010 · Cited by 61
Forsythe, S. D., Sivakumar, H., Erali, R. A., Wajih, N., Li, W., Shen, P., Levine, E. A., Miller, K. E., Skardal, A., & Votanopoulos, K. I. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12086-y · Cited by 61
“Thus, it is uncertain to what degree the PTOs in this study correlate with patient results, although others have shown promising efforts in relating PTO response to patient outcomes.(10,37) Finally, radiation in PTOs is an emerging field, but our study was not designed to incorporate this therapy.”
BackgroundResultMo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01642-5 · Cited by 60
“Organoids formed from patient-derived cancer cells can recapitulate patient responses in the clinic and are now used for evaluating drug sensitivity in various types of cancer, including breast cancer [23, 45].”
BackgroundPatient-derived tumor organoids as a platform of precision treatment for malignant brain tumors
Chen, C., Li, H.-W., Wang, Y., Lee, C.-C., Shen, Y.-C., Hsieh, C.-Y., Lin, H., Chen, X.-X., Cho, D., Hsieh, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20487-y · Cited by 63
Shu, D., Shen, M., Li, K., Han, X., Li, H., Tan, Z., Wang, Y., Peng, Y., Tang, Z., Qu, C., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2122550 · Cited by 63
“These organoids can be used to predict whether individual patients will respond to a drug.[30, 32, 33]”
BackgroundMolecular probes for in vivo optical imaging of immune cells
Liu, J., Cheng, P., Xu, C., & Pu, K. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01275-7 · Cited by 78
“In addition, in vitro systems, such as tissue chips 196–198 , patient-derived organoids 199–201 and other microphysiological systems 202 , can be used to recapitulate organ-level physiology and pathophysiology, including the immune system.”
Personalized Cancer Models for Target Discovery and Precision Medicine
Grandori, C., & Kemp, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.005 · Cited by 56
“Importantly, tumor derived organoid models phenotypically and genetically resemble the tumor from which they were derived [24, 40, 44, 45], enabling phenotypic analysis in the appropriate and personalized genetic context.”
BackgroundResultFGF Signalling in the Self-Renewal of Colon Cancer Organoids
Otte, J., Dizdar, L., Behrens, B., Goering, W., Knoefel, W. T., Wruck, W., Stoecklein, N. H., & Adjaye, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-53907-7 · Cited by 58
New technologies for developing phage-based tools to manipulate the human microbiome
Khan Mirzaei, M., & Deng, L. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.04.007 · Cited by 53
Berg, H. F., Hjelmeland, M. E., Lien, H. E., Espedal, H., Fonnes, T., Srivastava, A., Stokowy, T., Strand, E., Bozickovic, O., Stefansson, I. M., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00019-x · Cited by 61
Rapid tissue prototyping with micro-organospheres
Wang, Z., Boretto, M., Millen, R., Natesh, N. R., Reckzeh, E. S., Hsu, C., Negrete, M., Yao, H., Quayle, W. B., Heaton, B. E., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.07.016 · Cited by 61
Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
He, X., Jiang, Y. J., Zhang, L., Li, Y., Hu, X., Hua, G., Cai, S., Mo, S., & Peng, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1190637 · Cited by 66
“8%), including 24 primary CRC organoids, 15 metastatic liver organoids, 2 peritoneal metastatic organoids, and 1 ovarian metastatic organoid, which was in line with previous reports (Vlachogiannis et al., 2018; Lau et al., 2020).”
BackgroundResultHirst, J. J., Pathak, H. B., Hyter, S. D., Pessetto, Z. Y., Ly, T., Graw, S., Koestler, D. C., Krieg, A. J., Roby, K. F., & Godwin, A. K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3993 · Cited by 52
“Recent studies have suggested that 3D models will be predictive of patient response (16, 40) while our study focused on drugs with activity only in the 3D model, which would certainly have been overlooked by a traditional screening approach.”
BackgroundSensi, F., D’Angelo, E., Piccoli, M., Pavan, P. G., Mastrotto, F., Caliceti, P., Biccari, A., Corallo, D., Urbani, L., Fassan, M., et al. (2020) · Cancers · doi:10.3390/cancers12030681 · Cited by 57
Self-citationImplementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology
Dantes, Z., Yen, H.-Y., Pfarr, N., Winter, C., Steiger, K., Muckenhuber, A., Hennig, A., Lange, S., Engleitner, T., Öllinger, R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137809 · Cited by 56
Evaluation of cancer immunotherapy using mini-tumor chips
Ao, Z., Cai, H., Wu, Z., Hu, L., Li, X., Kaurich, C., Gu, M., Cheng, L., Lu, X., & Guo, F. (2022) · Theranostics · doi:10.7150/thno.71761 · Cited by 52
“The viable cells can then be subject to various treatments for drug response prediction treatment selection [14-19].”
BackgroundPatient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Park, M., Kwon, J., Kong, J., Moon, S. M., Cho, S., Yang, K. Y., Jang, W. I., Kim, M., Kim, Y., & Shin, U. S. (2021) · Cancers · doi:10.3390/cancers13153760 · Cited by 54
“For pancreatic cancer and metastatic gastrointestinal cancer, the PDTO models showed a high correlation with clinical outcomes in terms of drug response [19,20].”
BackgroundShen, X., Zhang, Y., Xu, Z., Gao, H., Feng, W., Li, W., Miao, Y., Xu, Z., Zong, Y., Zhao, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04773-1 · Cited by 56
“Drug screening assay We selected 60 FDA-approved anticancer drugs and small molecule compounds (Supplementary Data 2 and 3) from the Anti-cancer Compound Library (Supplementary Data 1) of Target Mol, which have been reported to be used for drug screening assays for digestive system tumors [4, 7].”
BackgroundMethodOrganoid assessment technologies
Gu, Y., Zhang, W. C., Wu, X., Zhang, Y., Xu, K., & Su, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1499 · Cited by 61
“8 Therefore, a future catalog of well-assessed organoids would pay more attention to quantify biological variation in presenting primary tissue in vivo and further solving the environmental perturbations on organoids in vitro models.”
BackgroundOrganoids from pluripotent stem cells and human tissues: When two cultures meet each other
Artegiani, B., & Hendriks, D. F. G. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.01.005 · Cited by 58
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
Li, K., Liu, C., Sui, X., Li, C., Zhang, T., Zhao, T., Zhang, D., Wu, H., Liu, Y., Wang, S., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.05.011 · Cited by 68
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
Sato, Y., Bolzenius, J. K., Eteleeb, A. M., Su, X., Maher, C. A., Sehn, J. K., & Arora, V. K. (2018) · JCI Insight · doi:10.1172/jci.insight.121062 · Cited by 52
“were derived, even when the drug targets aspects of the microenvironment, such as angiogenesis (31).”
BackgroundModeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors
Pasqualini, C., Kozaki, T., Bruschi, M., Nguyen, T. H. H., Minard‐Colin, V., Castel, D., Grill, J., & Ginhoux, F. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.018 · Cited by 59
He, L., Dai, W., Xia, X., Wang, R., Zhao, J., Han, L., Mo, S., Xiang, W., Du, L., Zhu, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00957-4 · Cited by 56
Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
Sondorp, L. H. J., Ogundipe, V. M. L., Groen, A. H., Kelder, W., Kemper, A., Links, T. P., Coppes, R. P., & Kruijff, S. (2020) · Cancers · doi:10.3390/cancers12113212 · Cited by 55
Popova, A. A., & Levkin, P. A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900100 · Cited by 51
Niklinska-Schirtz, B. J., Venkateswaran, S., Anbazhagan, M., Kolachala, V. L., Prince, J., Dodd, A., Chinnadurai, R., Gibson, G. C., Denson, L. A., Cutler, D. J., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.06.018 · Cited by 53
Tailored Biosensors for Drug Screening, Efficacy Assessment, and Toxicity Evaluation
Tao, Y., Chen, L., Pan, M., Zhu, F., & Zhu, D. (2021) · ACS Sensors · doi:10.1021/acssensors.1c01600 · Cited by 51
Hirokawa, Y., Clarke, J. E., Palmieri, M., Tan, T., Mouradov, D., Li, S., Lin, C., Li, F., Luo, H., Wu, K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02607-y · Cited by 56
Gastrointestinal cancer organoids—applications in basic and translational cancer research
Seidlitz, T., & Stange, D. E. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00654-3 · Cited by 58
Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
Cho, Y., Min, D., Kim, H., An, Y., Kim, S., Youk, J., Chun, J., Im, J. P., Song, S., Ju, Y. S., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13144 · Cited by 53
Tsai, K. K., Huang, S., Northey, J. J., Liao, W., Hsu, C., Cheng, L., Werner, M. E., Chuu, C., Chatterjee, C., Lakins, J. N., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00375-0 · Cited by 58
Chen, D., Su, X., Zhu, L., Hao, J., Han, B., Chen, H., Liang, Q., Hu, C., Yang, H., Liu, L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-022-03848-z · Cited by 51
“g, colorectal [4], prostate [5], lung [6], liver [7], breast [8], pancreatic [9], endometrial [10], bladder [11], ovarian [12], esophagus [13], and gastrointestinal [14] cancers.”
BackgroundAldea, M., Friboulet, L., Apcher, S., Jaulin, F., Mosele, F., Sourisseau, T., Soria, J.-C., Nikolaev, S., & André, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101642 · Cited by 47
Precision models in hepatocellular carcinoma
Bárcena‐Varela, M., Monga, S. P., & Lujambio, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01024-w · Cited by 62
“The ability of tumour organoids to predict patient responses have been confirmed in other tumour types, such as pancreatic ductal adenocarcinoma 71 , colorectal carcinoma 72,73 or gastrointestinal tumours 74 .”
Anandappa, G., Lampis, A., Cunningham, D., Khan, K. H., Kouvelakis, K., Vlachogiannis, G., Hedayat, S., Tunariu, N., Rao, S., Watkins, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3769 · Cited by 49
“Forty-two of those patients (88 cores) could be tested further in this study, as, following extensive previous analyses (5, 29), no cancer was left in three cases.”
MethodSelf-citationYoon, C., Till, J. E., Cho, S., Chang, K. K., Lin, J.-X., Huang, C., Ryeom, S. W., & Yoon, S. S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0077 · Cited by 50
“Mouse organoid studies Tcon3077 and Tcon3944 gastric tumors in Tcon mice were harvested, and organoids were isolated as previously described (16).”
MethodRetractedMini-gut: a promising model for drug development
Yin, Y., de Jonge, H. R., Wu, X., & Yin, Y. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.006 · Cited by 52
A Fast and Simple Fluorometric Method to Detect Cell Death in 3D Intestinal Organoids
Bode, K. J., Mueller, S., Schweinlin, M., Metzger, M., & Brunner, T. (2019) · BioTechniques · doi:10.2144/btn-2019-0023 · Cited by 49
The Prowess of Andrographolide as a Natural Weapon in the War against Cancer
Farooqi, A. A., Attar, R., Sabitaliyevich, U. Y., Alaaeddine, N., de Sousa, D. P., Xu, B., & Cho, W. C. S. (2020) · Cancers · doi:10.3390/cancers12082159 · Cited by 50
Biobanking of human gut organoids for translational research
Perrone, F., & Zilbauer, M. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00606-x · Cited by 57
Understanding the cellular origin and progression of esophageal cancer using esophageal organoids
Sachdeva, U. M., Shimonosono, M., Flashner, S. P., Cruz‐Acuña, R., Gabre, J. T., & Nakagawa, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.031 · Cited by 52
Organoids: A new approach in toxicity testing of nanotherapeutics
Nabi, S. U., Ali, S. I., Rather, M. A., Sheikh, W. M., Altaf, M., Singh, H., Mumtaz, P. T., Mishra, N. C., Nazir, S. U., & Bashir, S. M. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4206 · Cited by 47
“…N2, bovine serum albumin, EGF, noggin, R-spondin-1, gastrin, FGF10, FGF-basic, Wnt3A, prostaglandin E2, and nicotinamide A-83-01 Y27632 SB202190 Vlachogiannis et al. (2018) Liver cancer Basement membrane extract classical human liver organoid isolation medium: ADMEM/F12, penicillin/…”
Kim, S., Park, J. W., Seo, H., Kim, M. J., Park, J., Kim, G., Lee, J. O., Shin, Y., Bae, J. M., Koo, B., et al. (2021) · Advanced Science · doi:10.1002/advs.202103360 · Cited by 52
Jose, A., Kulkarni, P., Thilakan, J., Munisamy, M., Malhotra, A. G., Singh, J., Kumar, A., Rangnekar, V. M., Arya, N., & Rao, M. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01916-6 · Cited by 53
“V a l i d a t i o n o f P D O m o d e l u s i n g p a t i e n t d a t a [ 126 ] 3 .”
Frappart, P., & Hofmann, T. G. (2020) · Cancers · doi:10.3390/cancers12102750 · Cited by 59
“The feasibility and reliability of drug testing based on organoid cultures was first shown elegantly in gastrointestinal cancers by demonstrating that PDO exhibited 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value for the drug response [114].”
BackgroundSmyth, E. C., Vlachogiannis, G., Hedayat, S., Harbery, A., Wilson, S. H., Salati, M., Kouvelakis, K., Fernández-Mateos, J., Cresswell, G. D., Fontana, E., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322658 · Cited by 47
“…cells lines has so far hindered the pre-clinical testing of EGFRi in gastric Hereafter, using EGFR - amplified and non-amplified PDOs established from metastatic gastric adenocarcinomas 12 13 we provide experimental evidence of the antagonistic interaction between epirubicin and EGFRi in mGEA.”
Self-citationReconstructing the tumor architecture into organoids
Luo, Z., Zhou, X., Mandal, K., He, N., Wennerberg, W., Qu, M., Jiang, X., Sun, W., & Khademhosseini, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113839 · Cited by 52
Renner, H., Schöler, H. R., & Bruder, J. M. (2021) · Movement Disorders · doi:10.1002/mds.28775 · Cited by 49
Reustle, A., Menig-Benzig, L.-S., Leuthold, P., Hofmann, U., Stühler, V., Schmees, C., Becker, M., Haag, M., Klumpp, V., Winter, S., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.883 · Cited by 45
Living biobank-based cancer organoids: prospects and challenges in cancer research
Li, H., Liu, H., & Chen, K. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0621 · Cited by 54
Yin, S., Yu, Y., Wu, N., Zhuo, M., Wang, Y., Niu, Y., Ni, Y., Hu, F., Ding, C., Liu, H., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.03.008 · Cited by 54
Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
Wefers, C., Schreibelt, G., Massuger, L. F. A. G., de Vries, I. J. M., & Torensma, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01412 · Cited by 47
Wallaschek, N., Niklas, C., Pompaiah, M., Wiegering, A., Germer, C.-T., Kircher, S., Brändlein, S., Maurus, K., Rosenwald, A., Yan, H. H. N., et al. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.031 · Cited by 46
Mouse models of uveal melanoma: Strengths, weaknesses, and future directions
Richards, J. R., Yoo, J. H., Shin, D., & Odelberg, S. J. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12853 · Cited by 49
“3D cultures derived from patient tumor specimens can be grafted into mice (patient-derived organoid xenografts) and faithfully match the molecular phenotypes and even treatment responses of the source tumors (Sachs et al., 2018; Vlachogiannis et al., 2018).”
Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies
Pezzella, F., & Ribatti, D. (2020) · Cancer Reports · doi:10.1002/cnr2.1318 · Cited by 45
Liabeuf, D., Oshima, M., Stange, D. E., & Sigal, M. J. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.252 · Cited by 49
Hsu, K.-S., Adileh, M., Martin, M. L., Makarov, V., Chen, J., Wu, C., Bodo, S., Klingler, S., Sauvé, C.-E. G., Szeglin, B. C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4128 · Cited by 52
A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens
Price, S., Bhosle, S., Gonçalves, E., Li, X., McClurg, D. P., Barthorpe, S., Beck, A., Hall, C., Lightfoot, H., Farrow, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09508-y · Cited by 45
Flourishing tumor organoids: History, emerging technology, and application
Yang, Q., Li, M., Yang, X., Xiao, Z., Tong, X., Tuerdi, A., Li, S., & Lei, L. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10559 · Cited by 48
“Vlachogiannis et al.(200) established a living biobank for PDOs derived”
BackgroundOrganoids as Innovative Models for Bone and Joint Diseases
Huang, J., Zhang, L., Lü, A., & Liang, C. (2023) · Cells · doi:10.3390/cells12121590 · Cited by 51
The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors
Dougherty, M. W., Valdés‐Mas, R., Wernke, K. M., Gharaibeh, R. Z., Yang, Y., Brant, J. O., Riva, A., Muehlbauer, M., Elinav, E., Puschhof, J., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100918 · Cited by 50
“Colonoids were isolated from biopsies taken from healthy subjects undergoing routine colonoscopy as previously described [27].”
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith, I., Nurmik, M., Mencattini, A., Damei, I., Lansche, C., Brosseau, S., Gropplero, G., Corgnac, S., Filippi, J., Poté, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101549 · Cited by 63
“…evidence supporting the notion that they can recapitulate patient responses in the clinic to chemotherapies or targeted therapies for some cancers, 40–42 there are doubts regarding their utility for immunotherapy profiling for lung cancer patients, as they require long culture times (weeks) that…”
Inoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 45
Costales‐Carrera, A., Fernández‐Barral, A., Bustamante‐Madrid, P., Guerra, L., Cantero, R., Barbáchano, A., & Múñoz, A. (2019) · Marine Drugs · doi:10.3390/md17110648 · Cited by 52
“Organoid use was first supported by a study with organoids from 23 gastrointestinal cancer patients, showing 88% positive predictive value and, importantly, 100% negative predictive value [20].”
MethodClark, C., Yoo, K. M., Sivakumar, H., Strumpf, K., Laxton, A. W., Tatter, S. B., Strowd, R. E., III, & Skardal, A. (2022) · Biomedical Materials · doi:10.1088/1748-605x/aca05d · Cited by 52
Technologies to Assess Drug Response and Heterogeneity in Patient-Derived Cancer Organoids
Skala, M. C., Deming, D. A., & Kratz, J. D. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-123503 · Cited by 46
Recent advances in organoid engineering: A comprehensive review
Unagolla, J. M., & Jayasuriya, A. C. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101582 · Cited by 51
Advances in the application of 3D tumor models in precision oncology and drug screening
Guan, X., & Huang, S. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1021966 · Cited by 49
Mazzaglia, C., Sheng, Y., Rodrigues, L. N., Lei, I. M., Shields, J. D., & Huang, Y. Y. S. (2023) · Biofabrication · doi:10.1088/1758-5090/acb1db · Cited by 50
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing
Zu, M., Hao, X., Ning, J., Zhou, X., Gong, Y., Lang, Y., Xu, W., Zhang, J., & Ding, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114751 · Cited by 53
Modernizing Preclinical Drug Development: The Role of New Approach Methodologies
Mehta, K., Maaß, C., Cucurull-Sanchez, L., Pichardo‐Almarza, C., Subramanian, K., Androulakis, I. P., Gobburu, J. V. S., Schaller, S., & Sherwin, C. M. T. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00162 · Cited by 56
Kelm, J. M., Lal‐Nag, M., Sittampalam, G. S., & Ferrer, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.007 · Cited by 47
Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model
Klose, J., Trefz, S., Wagner, T., Steffen, L., Charrier, A. P., Radhakrishnan, P., Volz, C., Schmidt, T., Ulrich, A. B., Dieter, S. M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211916 · Cited by 48
Generation of 3D human gastrointestinal organoids: principle and applications
Zhang, M., Liu, Y., & Chen, Y. (2020) · Cell Regeneration · doi:10.1186/s13619-020-00040-w · Cited by 53
Lung organoids: advances in generation and 3D-visualization
Cunniff, B., Druso, J. E., & van der Velden, J. L. J. (2021) · Histochemistry and Cell Biology · doi:10.1007/s00418-020-01955-w · Cited by 50
Wang, J., Chen, C., Wang, L., Xie, M., Ge, X., Wu, S., He, Y., Mou, X., Ye, C., & Sun, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.872531 · Cited by 52
Scuto, M. C., Salinaro, A. T., Caligiuri, I., Ontario, M. L., Greco, V., Sciuto, N., Crea, R., Calabrese, E. J., Rizzolio, F., Canzonieri, V., et al. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111551 · Cited by 49
Gastric Organoids: Progress and Remaining Challenges
Pang, M.-J., Burclaff, J., Jin, R. U., Adkins-Threats, M., Osaki, L. H., Han, Y., Mills, J. C., Miao, Z., & Wang, Z.-N. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.005 · Cited by 50
Cancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 52
Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer
García, P., Rosa, L., Vargas-Salas, S., Weber, H. L., Espinoza, J. A., Suárez, F., Romero‐Calvo, I., Elgueta, N., Rivera, V., Nervi, B., et al. (2020) · Cancers · doi:10.3390/cancers12040778 · Cited by 45
“These findings are relevant considering that PDOs can emulate clinical drug response [19,42].”
BackgroundOrchestration of biomimetic membrane coating and nanotherapeutics in personalized anticancer therapy
Chen, X., Liu, B., Tong, R., Zhan, L., Yin, X., Luo, X., Huang, Y., Zhang, J., He, W., & Wang, Y. (2021) · Biomaterials Science · doi:10.1039/d0bm01617a · Cited by 47
Hydrogels to engineer tumor microenvironments in vitro
Fernando, K., Kwang, L. G., Lim, J. T. C., & Fong, E. L. S. (2021) · Biomaterials Science · doi:10.1039/d0bm01943g · Cited by 47
Extracellular Matrix-Based Hydrogels to Tailoring Tumor Organoids
Lee, H. J., Mun, S., Pham, D. M., & Kim, P. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01801 · Cited by 47
Lasolle, H., Schiavo, A. A., Tourneur, A., Gillotay, P., Fonseca, B. F., Ceolin, L., Monestier, O., Aganahi, B., Chomette, L., Kizys, M. M. L., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02889-y · Cited by 50
“These patient-derived organoids are particularly interesting in testing individual responses to therapies [21, 26, 27].”
Applications of lung cancer organoids in precision medicine: from bench to bedside
Li, H., Chen, Z., Chen, N., Fan, Y., Xu, Y., & Xu, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01332-9 · Cited by 52
He, S., Fang, Y., Wu, M., Zhang, P., Gao, F., Hu, H., Sheng, C., & Dong, G. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01539 · Cited by 42
Wagner, S., Vlachogiannis, G., Brandon, A. D. H., Valenti, M. R., Box, G., Jenkins, L., Mancusi, C., Self, A. J., Manodoro, F., Assiotis, I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0554-z · Cited by 47
Self-citationLi, J., Xu, H., Zhang, L., Song, L., Feng, D., Peng, X., Wu, M., Zou, Y., Wang, B., Zhan, L., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03004-z · Cited by 52
Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma
Ramzy, G. M., Koessler, T., Ducrey, E., McKee, T., Ris, F., Buchs, N. C., Rubbia‐Brandt, L., Dietrich, P., & Nowak-Sliwinska, P. M. (2020) · Cancers · doi:10.3390/cancers12061423 · Cited by 47
Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review
van der Beek, J. N., Geller, J. I., de Krijger, R. R., Graf, N. M., Pritchard‐Jones, K., Drost, J., Verschuur, A. C., Murphy, D., Ray, S., Spreafico, F., et al. (2020) · Cancers · doi:10.3390/cancers12071776 · Cited by 44
Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment
Hennig, A., Baenke, F., Klimová, A., Drukewitz, S., Jahnke, B., Brückmann, S., Secci, R., Winter, C., Schmäche, T., Seidlitz, T., et al. (2022) · The Journal of Pathology · doi:10.1002/path.5906 · Cited by 45
“The first study to correlate PDO response to treatment outcome was performed in gastrointestinal cancer, and other studies have provided additional evidence that patient response may be predicted by ex vivo testing [24,25].”
ResultXing, F., Liu, Y., Huang, S., Lyu, X., Su, S. M., Chan, U. I., Wu, P., Yan, Y., Ai, N., Li, J., et al. (2021) · Theranostics · doi:10.7150/thno.59533 · Cited by 46
“cancer drug discovery including cell-based assays [4, 5], zebrafish xenografts [6-8], patient derived xenografts (PDX) in mouse [9-11], and patientderived organoids (PDOs) model [12-15].”
BackgroundProstate organoids: emerging experimental tools for translational research
Beshiri, M. L., Agarwal, S., Yin, J. J., & Kelly, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169616 · Cited by 42
Breast cancer organoids derived from patients: A platform for tailored drug screening
Tzeng, Y. T., Hsiao, J., Tseng, L., Hou, M., & Li, C.-J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115803 · Cited by 49
Tan, T., Mouradov, D., Lee, M., Gard, G., Hirokawa, Y., Li, S., Lin, C., Li, F., Luo, H., Wu, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101335 · Cited by 60
“…definitive PDTO resistance, with discordance with patient outcome likely related to clonal heterogeneity as similarly reported in previous studies assessing multiple tumor biopsies or metastatic lesions 13,18,34 ; addressing this deficiency will require multiple-lesion sampling and assessment.”
BackgroundResult
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.